LY3305677 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight
Conditions
Overweight, Obesity
Trial Timeline
Nov 16, 2022 → Jun 27, 2023
NCT ID
NCT05623839About LY3305677 + Placebo
LY3305677 + Placebo is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT05623839. Target conditions include Overweight, Obesity.
What happened to similar drugs?
1 of 20 similar drugs in Overweight were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06124807 | Phase 2 | Completed |
| NCT05623839 | Phase 1 | Completed |
| NCT03928379 | Phase 1 | Completed |
| NCT03325387 | Phase 1 | Completed |
| NCT02972645 | Phase 1 | Completed |
Competing Products
20 competing products in Overweight